Huinan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huinan Zhang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Jingru Meng
2 shared publications- Xiaoxing Luo
Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi’an, China
2 shared publications Xue Ma
Department of Pharmacology, The Fourth Military Medical University, Xi'an, China
2 shared publications- Chen Ye
Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi’an, China
1 shared publication Di Qu
Department of Pharmacology, School of Pharmacy, the Fourth Military Medical University, Xi'an, China
1 shared publication- Gong-Hao He
Department of Clinical Pharmacy, Clinical College of the 920th Hospital, Kunming Medical University, Kunming, China
1 shared publication
Latest Publications
- Open Access
- 12 October 2021
- Published by Springer Nature in Oncogenesis
- Vol. 10 (10) , 1-13
TRPC1 promotes the genesis and progression of colorectal cancer via activating CaM-mediated PI3K/AKT signaling axis
Transient receptor potential canonical (TRPC) channels are the most prominent nonselective cation channels involved in various diseases. However, the function, clinical significance, and molecular mechanism of TRPCs in colorectal cancer (CRC) progression remain unclear. In this study, we identified that TRPC1 was the major variant gene of the TRPC family in CRC patients. TRPC1 was upregulated in CRC tissues compared with adjacent normal tissues and high expression of TRPC1 was associated with more aggressive tumor progression and poor overall survival. TRPC1 knockdown inhibited cell proliferation, cell-cycle progression, invasion, and migration in vitro, as well as tumor growth in vivo; whereas TRPC1 overexpression promoted colorectal tumor growth and metastasis in vitro and in vivo. In addition, colorectal tumorigenesis was significantly attenuated in Trpc1-/- mice. Mechanistically, TRPC1 could enhance the interaction between calmodulin (CaM) and the PI3K p85 subunit by directly binding to CaM, which further activated the PI3K/AKT and its downstream signaling molecules implicated in cell cycle progression and epithelial-mesenchymal transition. Silencing of CaM attenuated the oncogenic effects of TRPC1. Taken together, these results provide evidence that TRPC1 plays a pivotal oncogenic role in colorectal tumorigenesis and tumor progression by activating CaM-mediated PI3K/AKT signaling axis. Targeting TRPC1 represents a novel and specific approach for CRC treatment.
- 12 October 2021
- Published by Springer Nature in Oncogenesis
- Vol. 10 (10) , 1-13
Open AccessTRPC1 promotes the genesis and progression of colorectal cancer via activating CaM-mediated PI3K/AKT signaling axis
Transient receptor potential canonical (TRPC) channels are the most prominent nonselective cation channels involved in various diseases. However, the function, clinical significance, and molecular mechanism of TRPCs in colorectal cancer (CRC) progression remain unclear. In this study, we identified that TRPC1 was the major variant gene of the TRPC family in CRC patients. TRPC1 was upregulated in CRC tissues compared with adjacent normal tissues and high expression of TRPC1 was associated with more aggressive tumor progression and poor overall survival. TRPC1 knockdown inhibited cell proliferation, cell-cycle progression, invasion, and migration in vitro, as well as tumor growth in vivo; whereas TRPC1 overexpression promoted colorectal tumor growth and metastasis in vitro and in vivo. In addition, colorectal tumorigenesis was significantly attenuated in Trpc1-/- mice. Mechanistically, TRPC1 could enhance the interaction between calmodulin (CaM) and the PI3K p85 subunit by directly binding to CaM, which further activated the PI3K/AKT and its downstream signaling molecules implicated in cell cycle progression and epithelial-mesenchymal transition. Silencing of CaM attenuated the oncogenic effects of TRPC1. Taken together, these results provide evidence that TRPC1 plays a pivotal oncogenic role in colorectal tumorigenesis and tumor progression by activating CaM-mediated PI3K/AKT signaling axis. Targeting TRPC1 represents a novel and specific approach for CRC treatment.
- 1 October 2018
- Published by Elsevier in Experimental Neurology
- Vol. 308, 132-142
Inhibiting Jumoji domain containing protein 3 (JMJD3) prevent neuronal apoptosis from stroke
- 1 October 2018
- Published by Elsevier in Experimental Neurology
- Vol. 308, 132-142
Inhibiting Jumoji domain containing protein 3 (JMJD3) prevent neuronal apoptosis from stroke
- Open Access
- 1 April 2016
- Published by Elsevier in Stem Cell Reports
- Vol. 6 (4) , 633
Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin
- 1 April 2016
- Published by Elsevier in Stem Cell Reports
- Vol. 6 (4) , 633
Open AccessActivation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through β-Catenin
- 1 April 2015
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 70, 82-91
Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia
- 1 April 2015
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 70, 82-91
Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia